<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">medsovet</journal-id><journal-title-group><journal-title xml:lang="ru">Медицинский Совет</journal-title><trans-title-group xml:lang="en"><trans-title>Meditsinskiy sovet = Medical Council</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2079-701X</issn><issn pub-type="epub">2658-5790</issn><publisher><publisher-name>REMEDIUM GROUP Ltd.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.21518/2079-701X-2019-3-148-151</article-id><article-id custom-type="elpub" pub-id-type="custom">medsovet-3021</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ДИССЕРТАНТ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>DISSERTANT</subject></subj-group></article-categories><title-group><article-title>Фармакоэкономический анализ классических и альтернативных схем эрадикационной терапии инфекции Helicobacter pylori</article-title><trans-title-group xml:lang="en"><trans-title>Pharmacoeconomic analysis of classic and alternative eradication therapy regimens for Helicobacter pylori</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Велиев</surname><given-names>А. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Veliyev</surname><given-names>A. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>соискатель кафедры пропедевтики внутренних болезней и гастроэнтерологии,</p><p>127473, г. Москва, ул. Делегатская, д. 20, стр. 1</p></bio><bio xml:lang="en"><p>Applicant of the Department of Propaedeutics of Internal Diseases and Gastroenterology,</p><p>127473, Moscow, 20, Delegateskaya St., Moscow, Russia. 1</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Андреев</surname><given-names>Д. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Andreyev</surname><given-names>D. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>к.м.н., доцент кафедры пропедевтики внутренних болезней и гастроэнтерологии,</p><p>127473, г. Москва, ул. Делегатская, д. 20, стр. 1</p></bio><bio xml:lang="en"><p>Cand. of Sci. (Med.), Associate Professor of the Department of Pro paedeutics of Internal Diseases and Gastro enterology,</p><p>127473, Moscow, 20, Delegateskaya St., Moscow, Russia. 1</p></bio><email xlink:type="simple">dna-mit8@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Парцваниа-Виноградова</surname><given-names>Е. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Partsvania-Vinogradova</surname><given-names>E. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>аспирант кафедры пропедевтики внутренних болезней и гастроэнтерологии,</p><p>127473, г. Москва, ул. Делегатская, д. 20, стр. 1</p></bio><bio xml:lang="en"><p>Postgraduate student of the Department of Propaedeutics of Internal Diseases and Gastroenterology,</p><p>127473, Moscow, 20, Delegateskaya St., Moscow, Russia. 1</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Федеральное государственное бюджетное образовательное учреждение высшего образования «Московский государственный медико-стоматологический университет имени А.И. Евдокимова» Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Federal State Budgetary Educational Institution of Higher Education «Evdokimov Moscow State Medical and Dental University» of the Ministry of Health of the Russian Federation</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2019</year></pub-date><pub-date pub-type="epub"><day>12</day><month>05</month><year>2019</year></pub-date><volume>0</volume><issue>3</issue><fpage>148</fpage><lpage>151</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Велиев А.М., Андреев Д.Н., Парцваниа-Виноградова Е.В., 2019</copyright-statement><copyright-year>2019</copyright-year><copyright-holder xml:lang="ru">Велиев А.М., Андреев Д.Н., Парцваниа-Виноградова Е.В.</copyright-holder><copyright-holder xml:lang="en">Veliyev A.M., Andreyev D.N., Partsvania-Vinogradova E.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.med-sovet.pro/jour/article/view/3021">https://www.med-sovet.pro/jour/article/view/3021</self-uri><abstract><p>В статье приведены результаты фармакоэкономического анализа классических и альтернативных схем первой линии эрадикационной терапии инфекции Helicobacter pylori, используемых в российской практике. Наиболее выгодными с экономической точки зрения оказались последовательная терапия, квадротерапия с препаратом висмута и гибридная терапия. В свою очередь, с точки зрения клинико-экономического баланса наиболее оптимальными оказались такие схемы, как тройная терапия с добавлением препарата висмута, а также квадротерапия без препарата висмута.</p></abstract><trans-abstract xml:lang="en"><p>The article presents the results of pharmacoeconomic analysis of classical and alternative schemes of the first line of Helicobacter pylori eradication therapy used in Russian practice. The most profitable from the economic point of view were sequential therapy, quadrotherapy with bismuth drug and hybrid therapy. In turn, from the point of view of clinical and economic balance, such schemes as triple therapy with addition of bismuth drug, as well as quadrotherapy without bismuth drug were the most optimal.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>Helicobacter pylori</kwd><kwd>эрадикационная терапия</kwd><kwd>фармакоэкономика</kwd></kwd-group><kwd-group xml:lang="en"><kwd>Helicobacter pylori</kwd><kwd>eradication therapy</kwd><kwd>pharmacoeconomics</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Маев И.В., Андреев Д.Н. Инфекция Helicobacter pylori и ассоциированные заболевания. М.: Ремедиум, 2018.</mixed-citation><mixed-citation xml:lang="en">Maev I.V., Andreev D.N. Helicobacter pylori infection and associated diseases. M.: Remedium. 2018. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Malfertheiner P., Venerito M., Schulz C. Helicobacter pylori Infection: New Facts in Clinical Management. Curr Treat Options Gastroenterol. 2018 Dec;16(4):605-615.</mixed-citation><mixed-citation xml:lang="en">Malfertheiner P., Venerito M., Schulz C. Helicobacter pylori Infection: New Facts in Clinical Management. Curr Treat Options Gastroenterol. 2018 Dec;16(4):605-615.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">O’Morain N.R., Dore M.P., O’Connor A.J.P., Gisbert J.P., O’Morain C.A. Treatment of Helicobacter pylori infection in 2018. Helicobacter. 2018 Sep;23(Suppl 1):e12519.</mixed-citation><mixed-citation xml:lang="en">O’Morain N.R., Dore M.P., O’Connor A.J.P., Gisbert J.P., O’Morain C.A. Treatment of Helicobacter pylori infection in 2018. Helicobacter. 2018 Sep;23(Suppl 1):e12519.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Andreev D. Helicobacter pylori Eradication Therapy: Current Regimens. Adv. Res. Gastroenterol. Hepatol. 2017;7(2):555710. doi: 10.19080/ARGH.2017.07.555710.</mixed-citation><mixed-citation xml:lang="en">Andreev D. Helicobacter pylori Eradication Therapy: Current Regimens. Adv. Res. Gastroenterol. Hepatol. 2017;7(2):555710. doi: 10.19080/ARGH.2017.07.555710.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Самсонов А.А., Гречушников В.Б., Андреев Д.Н., Юренев Г.Л., Коровина Т.И., Лежнева Ю.А., Маев И.В. Оценка фармакоэкономических показателей лечения пациентов с заболеваниями, ассоциированными с Helicobacter pylori. Терапевтический архив. 2014;8:57-61.</mixed-citation><mixed-citation xml:lang="en">Samsonov A.A., Grechushnikov V.B., Andreev D.N., Yureniev G.L., Korovina T.I., Lezhneva Y.A., Maev I.V. Evaluation of pharmacoeconomic indicators of treatment of patients with diseases associated with Helicobacter pylori. Therapeutic archive [Terapevticheskij arhiv]. 2014;8:57-61. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Воробьев П.А. Клинико-экономический анализ. Издание 3-е. М.: «Ньюдиамед», 2008.: 778 с. [Vorobiev P.A. Clinical and economic analysis. 3-rd edition. M.: «Newdiamed», 2008.: 778 p.] (In Russ.)</mixed-citation><mixed-citation xml:lang="en">Vorobiev P.A. Clinical and economic analysis. 3-rd edition. M.: «Newdiamed», 2008.: 778 p. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Андреев Д.Н., Дичева Д.Т., Маев И.В. Возможности оптимизации эрадикационной терапии инфекции Helicobacter pylori в современной клинической практике. Терапевтический архив. 2017;2:76-83</mixed-citation><mixed-citation xml:lang="en">Andreev D.N., Dicheva D.T., Maev I.V. Possibilities of optimization of eradication therapy of Helicobacter pylori infection in modern clinical practice. Therapeutic archive [Terapevticheskij arhiv]. 2017;2:76-83. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Велиев А.М., Маев И.В., Андреев Д.Н., Дичева Д.Т., Лобанова Е.Г., Бектемирова Л.Г. Эффективность и безопасность квадротерапии без препаратов висмута при лечении пациентов с Helicobacter pylori-ассоциированной язвенной болезнью желудка и двенадцатиперстной кишки. Терапевтический архив. 2019;8: принято к печати.</mixed-citation><mixed-citation xml:lang="en">Veliyev A.M., Maev I.V., Andreyev D.N., Dicheva D.T., Lobanova E.G., Bektemirova L.G. Efficacy and safety of quadrotherapy without bismuth drugs in treatment of patients with Helicobacter pylori-associated stomach and duodenal ulcer. Therapeutic archive [Terapevticheskij arhiv]. 2019;8: accepted for publishing. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Бордин Д.С., Машарова А.А., Хомерики С.Г. Хронический гастрит: современный взгляд на старую проблему. Эксперимент. и клин. гастроэнтерол. 2012;5:99-106.</mixed-citation><mixed-citation xml:lang="en">Bordin D.S., Masharova A.A., Homeriki S.G. Chronic gastritis: a modern view of the old problem. Experimental. and clin. gastroenterol [Jeksperiment. i klin. Gastrojenterol.]. 2012;5:99-106. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Андреев Д.Н., Маев И.В., Дичева Д.Т., Самсонов А.А., Парцваниа-Виноградова Е.В. Эффективность и безопасность применения ребамипида в схеме тройной эрадикационной терапии инфекции Helicobacter pylori: проспективное рандомизированное сравнительное исследование. Терапевтический архив. 2018;90(8):27-32.</mixed-citation><mixed-citation xml:lang="en">Andreev D.N., Maev I.V., Dicheva D.T., Samsonov A.A., PartsvaniaVinogradova E.V. Efficacy and safety of rebamipid application in the scheme of triple eradication therapy of infection Helicobacter pylori: prospective randomized comparative study. Therapeutic archive [Terapevticheskij arhiv]. 2018;90(8):27-32. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Андреев Д.Н., Маев И.В., Кучерявый Ю.А., Дичева Д.Т., Парцваниа-Виноградова Е.В. Эффективность и безопасность антихеликобактерной терапии у пациентов с сопутствующим хроническим гепатитом С. Терапевтический архив. 2016;88(4):75-81.</mixed-citation><mixed-citation xml:lang="en">Andreev D.N., Maev I.V., Kucheryavy Y.A., Dicheva D.T, Partsvania-Vinogradova E.V. Efficacy and safety of anti-Helicobacter therapy in patients with concomitant chronic hepatitis C. Therapeutic archive [Terapevticheskij arhiv].2016;88(4):75- 81. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Юренев Г.Л., Парцваниа-Виноградова Е.В., Андреев Д.Н., Дичева Д.Т., Маев И.В. Оценка эффективности и безопасности гибридной схемы эрадикационной терапии инфекции Helicobacter pylori. Терапевтический архив. 2018;90(8):33-39.</mixed-citation><mixed-citation xml:lang="en">Yurenev G.L., PartsvaniaVinogradova E.V., Andreev D.N., Dicheva D.T., Maev I.V. Efficacy and safety assessment of the hybrid scheme of eradication therapy of Helicobacter pylori infection. Therapeutic archive [Terapevticheskij arhiv]. 2018;90(8):33- 39. (In Russ.)</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
